s (TAA) to the forefront as key liquid biopsy biomarkers, demonstrating intriguing and encouraging results for early diagnosis and prognostic evaluation of lung cancer. This review provides an overview of molecular biomarkers and assays utilized in liquid biopsies for lung cancer, encompassing CTCs, ct...
Raez, MD, medical director of Memorial Cancer Institute, and chief of Hematology/Oncology at Memorial Healthcare System, to discuss the evolution of liquid biopsy in lung cancer.Liquid biopsy continues to gain traction in the field of oncology, augmenting traditional tissue biopsy and broadening the...
as it has several advantages such as non-invasive, real-time dynamic monitoring, and overcoming tumor heterogeneity. Liquid biopsy has shown predictive value in immunotherapy, significantly improving the precision treatment of lung cancer patients. Herein, we review the application of ...
Lung cancer screening is currently based only on low-dose CT scans; however, novel, more accessible methods that might improve uptake and adherence are eagerly awaited. New liquid biopsy approaches promise to revolutionize cancer screening. Herein, we discuss the opportunities and challenges associated...
Liquid biopsies in lung cancer: The new ambrosia of researchers ChristianRolfo, ...PatrickPauwels, inBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2014 Highlights • The review underlies the potential impact ofliquid biopsyin lung cancer patients management. ...
Liquid biopsy has shown predictive value in immunotherapy, significantly improving the precision treatment of lung cancer patients. Herein, we review the application of liquid biopsy in predicting the outcomes of immunotherapy in NSCLC patients, and discuss the challenges and future directions in this ...
LifeOS Genomics is dedicated to building the most uncompromising liquid biopsy platform yet, and developing clinical solutions for complex genetic diseases.
Liquid biopsy has been widely researched for early diagnosis, prognostication and disease monitoring in lung cancer, but there is a need to investigate its clinical utility for early-stage non-small cell lung cancer (NSCLC). We performed a meta-analysis
Pleural effusion containing rare disseminated metastatic tumor cells represents a valuable surrogate for the tumor tissue biopsy and allows us to interrogate the metabolic state of patient tumor cells. Pleural effusion is a common complication and often the first sign of lung cancer patients18,19. Com...
Cancer has a high mortality rate across the globe, and tissue biopsy remains the gold standard for tumor diagnosis due to its high level of laboratory standardization, good consistency of results, relatively stable samples, and high accuracy of results.